Monte Financial Group LLC increased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 92.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,925 shares of the medical instruments supplier's stock after acquiring an additional 1,883 shares during the period. Monte Financial Group LLC's holdings in West Pharmaceutical Services were worth $1,178,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Fidelis Capital Partners LLC bought a new position in shares of West Pharmaceutical Services during the first quarter valued at $27,000. Northwest Investment Counselors LLC bought a new stake in West Pharmaceutical Services during the third quarter worth about $30,000. Crewe Advisors LLC grew its stake in West Pharmaceutical Services by 322.7% during the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 71 shares during the last quarter. ORG Partners LLC increased its holdings in shares of West Pharmaceutical Services by 820.0% during the first quarter. ORG Partners LLC now owns 138 shares of the medical instruments supplier's stock worth $55,000 after buying an additional 123 shares in the last quarter. Finally, Quest Partners LLC boosted its holdings in shares of West Pharmaceutical Services by 5,633.3% in the 2nd quarter. Quest Partners LLC now owns 172 shares of the medical instruments supplier's stock worth $57,000 after acquiring an additional 169 shares in the last quarter. Institutional investors own 93.90% of the company's stock.
Insider Buying and Selling at West Pharmaceutical Services
In other news, VP Charles Witherspoon sold 1,029 shares of the company's stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the transaction, the vice president now directly owns 1,478 shares in the company, valued at approximately $443,400. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.53% of the company's stock.
West Pharmaceutical Services Price Performance
NYSE WST traded up $44.21 during trading hours on Thursday, reaching $330.65. 1,983,586 shares of the company's stock were exchanged, compared to its average volume of 558,379. The firm has a fifty day moving average of $299.60 and a 200-day moving average of $322.81. West Pharmaceutical Services, Inc. has a one year low of $265.00 and a one year high of $413.70. The stock has a market cap of $23.99 billion, a PE ratio of 49.50, a price-to-earnings-growth ratio of 10.21 and a beta of 1.01. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing analysts' consensus estimates of $1.74 by ($0.22). The business had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business's quarterly revenue was down 6.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.11 earnings per share. On average, equities research analysts predict that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.
About West Pharmaceutical Services
(
Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Further Reading
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
